The standard protocol for fertility preservation in patients with cancer includes stimulation with a gonadotropin releasing hormone (GnRH) antagonist protocol, and final maturation induction with a GnRH agonist, which is known to reduce the risk of ovarian hyperstimulation syndrome (OHSS) compared to a human chorionic gonadotropin (hCG) trigger [32]. The gene discussed is GNRH1; the disease is cancer.